首页> 美国卫生研究院文献>Journal of Clinical and Diagnostic Research : JCDR >A Combination Strategy of Ceftriaxone Sulbactam and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A Retrospective Observational Study in Indian Tertiary Care Hospital

【2h】

A Combination Strategy of Ceftriaxone Sulbactam and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A Retrospective Observational Study in Indian Tertiary Care Hospital

机译：头孢曲松舒巴坦和乙二胺四乙酸二钠联合治疗多药耐药（MDR）败血症的策略：印度三级医院的回顾性观察研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionPrevious studies have suggested the use of rational combination therapy for the treatment of multi-drug resistant (MDR) infections. An antibiotic adjuvant entity (AAE) of ceftriaxone, sulbactam and disodium edetate (Elores) was approved for multi-drug resistant infections in India.

机译：引言先前的研究表明，合理的联合疗法可用于治疗多药耐药性（MDR）感染。头孢曲松，舒巴坦和乙二胺四乙酸二钠（Elores）的抗生素佐剂实体（AAE）在印度已被批准用于多重耐药性感染。

著录项

期刊名称 Journal of Clinical and Diagnostic Research : JCDR
作者
Umakant Nagashetty Patil; Kiran Lakkol Jambulingappa;
展开▼
作者单位

展开▼
年(卷),期 2015(9),11
年度 2015
页码 FC29–FC32
总页数 4
原文格式 PDF
正文语种
中图分类
关键词
Antibiotic adjuvant entity Bacterial septicaemia Combination therapy;

机译：抗生素佐剂实体;细菌性败血症;联合治疗;

相似文献

外文文献
中文文献

1. A Combination Strategy of Ceftriaxone, Sulbactam and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A Retrospective, Observational Study in Indian Tertiary Care Hospital [J] . Umakant Nagashetty Patil, Kiran Lakkol Jambulingappa Journal of Clinical and Diagnostic Research . 2015,第11期

机译：头孢曲松，舒巴坦和依地酸二钠的联合治疗多药耐药性（MDR）败血病的策略：印度三级医院的回顾性观察研究。
2. Antibiotic/Adjuvant Combinations (Ceftriaxone+Sulbactam+Disodium Edetate) to Combat Multi-Drug Resistant Gram Negative Bacterial Infections-A New Therapeutic Strategy [J] . Prashant Bhatia, Danish Jamal National Journal of Laboratory Medicine . 2018,第3期

机译：抗生素/佐剂组合（头孢曲松钠+舒巴坦+依地酸二钠）与多药耐药革兰氏阴性菌感染作斗争-一种新的治疗策略
3. A New Fixed Dose Combination of Ceftriaxone + Sulbactam + Disodium Edetate for Definitive Treatment of Infections Due to Piperacillin/ Tazobactam Resistant Bacteria: A Retrospective Efficacy and Pharmacoeconomic Study [J] . British Journal of Medicine and Medical Research . 2016,第4期

机译：头孢曲松+舒巴坦+乙二胺四乙酸二钠的新型固定剂量组合用于确定性治疗哌拉西林/他唑巴坦耐药细菌引起的感染：回顾性疗效和药物经济学研究
4. Evaluation of ceftriaxone-sulbactam-disodium edetate adjuvant combination against multi-drug resistant Gram-negative organisms [O] . Shilpi Gupta, Mahadevan Kumar, Shelinder P.S. Shergill, 2020

机译：对多药抗革兰阴性生物的CeFtriaxone-sulbactam-二钠辅酶辅助组合的评价
5. Safety and efficacy of a novel drug elores (ceftriaxone + sulbactam + disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study [O] . Manu Chaudhary, Mohd Amin Mir, Shiekh Gazalla Ayub 2017

机译：新型药物elores（头孢曲松+舒巴坦+乙二胺四乙酸二钠）在三级医疗中心多重耐药细菌感染管理中的安全性和有效性：上市后监测研究

A Combination Strategy of Ceftriaxone Sulbactam and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A Retrospective Observational Study in Indian Tertiary Care Hospital

摘要

著录项

相似文献

相关主题

期刊订阅